Welcome to the SUPER-CAT official site!

What is SUPER-CAT? SUPER-CAT stands for “Study of the Utility of Rivaroxaban or Clopidogrel for prevention of recurrent Arterial Thromboembolism in cats.”  This study is funded by the Morris Animal Foundation and aims to investigate the efficacy of a novel anti-clotting drug (rivaroxaban) compared to clopidogrel in preventing the recurrence of arterial thromboembolism (“saddle thrombus”) in cats with heart disease. Information gained from this study will help researchers improve treatments and clinical management strategies to delay or prevent these often-fatal clotting complications in cats with heart disease.

Qualified participants include cats with heart disease that have survived an arterial thromboembolism.

If you are the owner of a cat that you think qualifies for the study, please click here.

If you are a veterinarian and treating a cat with a cardiogenic thromboembolism that can qualify for the SUPER-CAT study, please click here.

The lead investigator of the SUPER-CAT study is Dr. Benjamin Brainard, a critical care specialist at the College of Veterinary Medicine of the University of Georgia.